Literature DB >> 25870334

Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Ayman K Hamouda1, Ze-Jun Wang1, Deirdre S Stewart1, Atul D Jain1, Richard A Glennon1, Jonathan B Cohen2.   

Abstract

Desformylflustrabromine (dFBr) is a positive allosteric modulator (PAM) of α4β2 and α2β2 nAChRs that, at concentrations >1 µM, also inhibits these receptors and α7 nAChRs. However, its interactions with muscle-type nAChRs have not been characterized, and the locations of its binding site(s) in any nAChR are not known. We report here that dFBr inhibits human muscle (αβεδ) and Torpedo (αβγδ) nAChR expressed in Xenopus oocytes with IC50 values of ∼ 1 μM. dFBr also inhibited the equilibrium binding of ion channel blockers to Torpedo nAChRs with higher affinity in the nAChR desensitized state ([(3)H]phencyclidine; IC50 = 4 μM) than in the resting state ([(3)H]tetracaine; IC50 = 60 μM), whereas it bound with only very low affinity to the ACh binding sites ([(3)H]ACh, IC50 = 1 mM). Upon irradiation at 312 nm, [(3)H]dFBr photoincorporated into amino acids within the Torpedo nAChR ion channel with the efficiency of photoincorporation enhanced in the presence of agonist and the agonist-enhanced photolabeling inhibitable by phencyclidine. In the presence of agonist, [(3)H]dFBr also photolabeled amino acids in the nAChR extracellular domain within binding pockets identified previously for the nonselective nAChR PAMs galantamine and physostigmine at the canonical α-γ interface containing the transmitter binding sites and at the noncanonical δ-β subunit interface. These results establish that dFBr inhibits muscle-type nAChR by binding in the ion channel and that [(3)H]dFBr is a photoaffinity probe with broad amino acid side chain reactivity.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25870334      PMCID: PMC4468644          DOI: 10.1124/mol.115.098913

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  59 in total

1.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

2.  Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: serine-262 of the delta subunit is labeled by [3H]chlorpromazine.

Authors:  J Giraudat; M Dennis; T Heidmann; J Y Chang; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

3.  The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating.

Authors:  G N Filatov; M M White
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

4.  Identifying the lipid-protein interface of the Torpedo nicotinic acetylcholine receptor: secondary structure implications.

Authors:  M P Blanton; J B Cohen
Journal:  Biochemistry       Date:  1994-03-15       Impact factor: 3.162

5.  Mapping of the acetylcholine binding site of the nicotinic acetylcholine receptor: [3H]nicotine as an agonist photoaffinity label.

Authors:  R E Middleton; J B Cohen
Journal:  Biochemistry       Date:  1991-07-16       Impact factor: 3.162

6.  Agonist-induced changes in the structure of the acetylcholine receptor M2 regions revealed by photoincorporation of an uncharged nicotinic noncompetitive antagonist.

Authors:  B H White; J B Cohen
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

7.  Conformational changes in the nicotinic acetylcholine receptor during gating and desensitization.

Authors:  Innocent H Yamodo; David C Chiara; Jonathan B Cohen; Keith W Miller
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

8.  Photolabeling of membrane-bound Torpedo nicotinic acetylcholine receptor with the hydrophobic probe 3-trifluoromethyl-3-(m-[125I]iodophenyl)diazirine.

Authors:  B H White; J B Cohen
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

9.  Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors.

Authors:  C Labarca; M W Nowak; H Zhang; L Tang; P Deshpande; H A Lester
Journal:  Nature       Date:  1995-08-10       Impact factor: 49.962

10.  Crystal structure of a human GABAA receptor.

Authors:  Paul S Miller; A Radu Aricescu
Journal:  Nature       Date:  2014-06-08       Impact factor: 49.962

View more
  11 in total

Review 1.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

2.  Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses.

Authors:  Ze-Jun Wang; Farah Deba; Tasnim S Mohamed; David C Chiara; Kara Ramos; Ayman K Hamouda
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

3.  Enantiomeric barbiturates bind distinct inter- and intrasubunit binding sites in a nicotinic acetylcholine receptor (nAChR).

Authors:  Zhiyi Yu; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2017-09-06       Impact factor: 5.157

4.  Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric Modulator.

Authors:  Ayman K Hamouda; Farah Deba; Ze-Jun Wang; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2016-03-14       Impact factor: 4.436

Review 5.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

6.  Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.

Authors:  Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

7.  LY2087101 and dFBr share transmembrane binding sites in the (α4)3(β2)2 Nicotinic Acetylcholine Receptor.

Authors:  Farah Deba; Hamed I Ali; Abisola Tairu; Kara Ramos; Jihad Ali; Ayman K Hamouda
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

8.  Examining the Effects of (α4)3(β2)2 Nicotinic Acetylcholine Receptor-Selective Positive Allosteric Modulator on Acute Thermal Nociception in Rats.

Authors:  Farah Deba; Kara Ramos; Matthew Vannoy; Kemburli Munoz; Lois S Akinola; M Imad Damaj; Ayman K Hamouda
Journal:  Molecules       Date:  2020-06-25       Impact factor: 4.411

9.  Nicotinic Acetylcholine Receptor Partial Antagonist Polyamides from Tunicates and Their Predatory Sea Slugs.

Authors:  Noemi D Paguigan; Jortan O Tun; Lee S Leavitt; Zhenjian Lin; Kevin Chase; Cheryl Dowell; Cassandra E Deering-Rice; Albebson L Lim; Manju Karthikeyan; Ronald W Hughen; Jie Zhang; Randall T Peterson; Christopher A Reilly; Alan R Light; Shrinivasan Raghuraman; J Michael McIntosh; Baldomero M Olivera; Eric W Schmidt
Journal:  ACS Chem Neurosci       Date:  2021-07-02       Impact factor: 5.780

Review 10.  Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation.

Authors:  Tasnim S Mohamed; Selwyn S Jayakar; Ayman K Hamouda
Journal:  Front Mol Neurosci       Date:  2015-11-25       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.